Harvard Apparatus Regenerative Technology, Inc.

For the period ended Mar 31, 2026. Filed May 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 13, 2026

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’** EQUITY**

(in thousands, except share data)

Number of · Accumulated
Common · Additional · Other · Total
	Shares	Common	Paid-in	Accumulated	Comprehensive	Stockholders’
	Outstanding	Stock	Capital	Deficit	Loss	Equity
Balance at January 1, 2026	17,580,744	$176	$107,450	$(106,557)	$(12)	$1,057
Share-based compensation expense	—	—	632	—	—	632
Net loss	—	—	—	(1,601)	—	(1,601)
Other comprehensive loss	—	—	—	—	4	4
Balance at March 31, 2026	17,580,744	$176	$108,082	$(108,158)	$(8)	$92

Number of · Accumulated
Common · Additional · Other · Total
	Shares	Common	Paid-in	Accumulated	Comprehensive	Stockholders’
	Outstanding	Stock	Capital	Deficit	Loss	Equity
Balance at January 1, 2025	15,918,979	$159	$102,757	$(99,688)	$(6)	$3,222
Share-based compensation expense	—	—	485	—	—	485
Net loss	—	—	—	(1,659)	—	(1,659)
Balance at March 31, 2025	15,918,979	$159	$103,242	$(101,347)	$(6)	$2,048

See accompanying notes to unaudited condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.